FindTrial
Sign In

Treatment of physician's choice (TPC)

DRUG2 trials

Sponsors

Nektar Therapeutics, Fudan University

Conditions

Advanced Breast CancerBreast CancerHER2-negative Breast CancerLocally Recurrent Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer (TNBC)

Phase 2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
RecruitingNCT06649331
Fudan UniversityAdvanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC) +2
Start: 2024-10-21End: 2027-09-01Target: 160Updated: 2026-09-03

Phase 3

The BEACON Study (Breast Cancer Outcomes With NKTR-102)
CompletedNCT01492101
Nektar TherapeuticsLocally Recurrent Breast Cancer, Metastatic Breast Cancer
Start: 2011-12-31End: 2016-06-30Updated: 2021-06-01

Related Papers

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
2017-03-2712 citations
Abstract P4-11-08: Impact of treatment on quality of life (QOL) in the BEACON study, a randomized phase III trial of etirinotecan pegol (EP) versus treatment of physician's choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C)
Cancer Research2016-02-151 citations
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
2015-10-2256 citations
Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.
Journal of Clinical Oncology2015-05-207 citations